Comparison of Chemical Peeling Agent With Transamine for Treatment of Melasma

• Status: Completed
• Trial end date: 2021-11-30
• Target enrollment: 0
• Participant gender: All

Summary

Melasma is an acquired skin disorder characterized by hyper-melanosis. Melasma is a term that originates from the Greek root "melas" (black color) and was formerly known as chloasma. Melasma is more common in sun-exposed tissues such as the cheeks, chin, upper lip, and forehead. Melasma is a common dermatological disorder with a frequency of 8.8 percent in the United States, but it can be as high as 40 percent amongst females. Melasma affects mostly ladies and is most common throughout their reproductive years .

Melasma causes an increase in melanin pigment synthesis owing to a surge in the number of melanosomes, which are membrane-bound cell organelles inside melanocytes where melanin biosynthesis occurs and is transported to keratinocytes. Except in rare situations, the number of melanocytes will not be enhanced. Melanocytes will grow in size, and dendrites will become more visible. Despite the fact that the specific causation is unknown, some elements are thought to have a role in the pathophysiological mechanisms of melasma). Among these, sun exposure (UV light) is the most powerful primary trigger for its growth, which explains melisma's propensity for certain areas of the body. Other major determinants include genetic predisposition, and female hormones - both endogenous (that is, during pregnancy) and exogenous (that is, during pregnancy) (contraceptives and hormone replacement therapy). Thyroid problems, medications, and cosmetics can all be aggravating factors. Evaluation and prevention of triggering variables are essential in order to avoid recurrence .

The peeling effect of glycolic acid is due to chemo exfoliation capabilities, that rely upon aiding the elimination of keratinocytes, resulting in melanin reduction and speeding up the regeneration of skin. TA suppresses UV-stimulated plasmin action in keratin cells by blocking plasminogen appending to the keratin cells, resulting from lower free arachidonic acid levels or to reduced capacity of prostaglandins production, which reduces melanocyte tyrosinase activity .

The study's implications are to analyze the efficacy of these two drugs in order to assess the better outcome of patients with evidence-based management.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Combined Military Hospital Abbottabad
• Treatments: Glycolic acid; Tranexamic Acid; Tranylcypromine

Criteria

Inclusion Criteria:

• patients suffering from Melasma who attended the Dermatology department

Exclusion Criteria:

• history of hormone therapy and contraceptive pills (within the previous 12 months)

• bleeding problems or concurrent use of anticoagulants

• Topical treatment such as hydroquinone (one month prior to the research)

• Active herpes simplex, face warts or active dermatoses

• History of hypersensitivity to some of the study's components

• Pregnant or lactating females

• Patients with unrealistic expectations